Skip to main content
. Author manuscript; available in PMC: 2014 Jan 1.
Published in final edited form as: Clin Gastroenterol Hepatol. 2012 Aug 31;11(1):57–62. doi: 10.1016/j.cgh.2012.08.032

Table 2.

Risk of CD and UC According to Recent MHI-5 Scorea

MHI-5 score
86–100		 MHI-5 score
76–85		 MHI-5 score
53–75		 Depressive symptoms
0–52		 P linear
trend
Person-years of follow-up
 478,480 616,292 516,500 175,798
CD
 No. of cases 33 57 53 27
 Age-adjusted incidenceb 7 9 10 15
 Age-adjusted HR (95% CI) 1.0 1.41 (0.91–2.17) 1.65 (1.06–2.57) 2.55 (1.51–4.29) .0003
 Multivariate HR (95% CI)c 1.0 1.38 (0.90–2.13) 1.59 (1.02–2.48) 2.36 (1.40–3.99) .0010
UC
 No. of cases 48 68 65 22
 Age-adjusted incidenceb 10 11 13 13
 Age-adjusted HR (95% CI) 1.0 1.07 (0.73–1.55) 1.19 (0.81–1.74) 1.19 (0.71–1.98) .4000
 Multivariate HR (95% CI)c 1.0 1.05 (0.72–1.53) 1.16 (0.79–1.70) 1.14 (0.68–1.92) .4900

NOTE. P value for linear trend was calculated by modeling the median MHI-5 value for each stratum as a linear variable.

a

Recent depressive symptoms refer to MHI administered within 4 years of follow-up.

b

Per 100,000 person-years.

c

Adjusted for age, cohort, race (white, nonwhite), smoking (never, past, current), BMI (<20, 20–24.9, 25–29, ≥30 kg/m2), oral contraceptive use (never, past, current), use of PMH therapy (premenopausal, PMH never user, past user, current user), regular use of NSAIDs (yes, no), regular use of aspirin (yes, no).